These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7990300)

  • 1. [Assay of urinary pyridinoline and deoxypyridinoline as potential markers of the rate of bone resorption: usefulness of urinary pyridinoline and deoxypyridinoline in patients with prostate cancer with bone metastases].
    Takeuchi S; Yoshida K
    Nihon Hinyokika Gakkai Zasshi; 1994 Oct; 85(10):1521-7. PubMed ID: 7990300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
    Miyamoto KK; McSherry SA; Robins SP; Besterman JM; Mohler JL
    J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer.
    Takeuchi S; Arai K; Saitoh H; Yoshida K; Miura M
    J Urol; 1996 Nov; 156(5):1691-5. PubMed ID: 8863572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis.
    Sano M; Kushida K; Takahashi M; Ohishi T; Kawana K; Okada M; Inoue T
    Br J Cancer; 1994 Oct; 70(4):701-3. PubMed ID: 7917922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The clinical usefulness of urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer].
    Takeuchi S; Saitoh H
    Nihon Rinsho; 1998 Aug; 56(8):2077-81. PubMed ID: 9750511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential changes of urinary pyridinoline and deoxypyridinoline as markers of metastatic bone tumor in patients with prostate cancer: a preliminary study.
    Samma S; Kagebayashi Y; Yasukawa M; Fukui Y; Ozono S; Hirao Y; Sato H; Okajima E
    Jpn J Clin Oncol; 1997 Feb; 27(1):26-30. PubMed ID: 9070337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Studies of type I collagen related substances as bone metastatic markers of prostate carcinoma with special regard to serum carboxyterminal propeptide of type. I. Procollagen (PICP), cross-linked carboxyterminal telopeptide of type I collagen (ICTP) and Urinary deoxypyridinoline levels].
    Imai T; Honda M; Maeda S; Hosoya Y; Arai T; Sumi S; Umeda H; Yano M; Koga F; Arai K; Yoshida K
    Nihon Hinyokika Gakkai Zasshi; 1998 Apr; 89(4):484-91. PubMed ID: 9597867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of clodronate in patients with multiple myeloma. Evaluation of specific markers of bone resorption].
    Slabý J; Spicka I; Hulejová H; Spacek P; Cieslar P; Klener P
    Cas Lek Cesk; 1997 Jan; 136(2):57-60. PubMed ID: 9147856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy.
    Tamada T; Sone T; Tomomitsu T; Jo Y; Tanaka H; Fukunaga M
    J Bone Miner Metab; 2001; 19(1):45-51. PubMed ID: 11156473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links.
    Uebelhart D; Schlemmer A; Johansen JS; Gineyts E; Christiansen C; Delmas PD
    J Clin Endocrinol Metab; 1991 Feb; 72(2):367-73. PubMed ID: 1991806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer.
    Ikeda I; Miura T; Kondo I
    Br J Urol; 1996 Jan; 77(1):102-6. PubMed ID: 8653278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia.
    Body JJ; Delmas PD
    J Clin Endocrinol Metab; 1992 Mar; 74(3):471-5. PubMed ID: 1740478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone-turnover metabolites as clinical markers of bone metastasis in patients with prostatic carcinoma.
    Takeuchi S; Saitoh H
    Int J Urol; 1997 Jul; 4(4):368-73. PubMed ID: 9256326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis.
    Wymenga LF; Groenier K; Schuurman J; Boomsma JH; Elferink RO; Mensink HJ
    BJU Int; 2001 Aug; 88(3):231-5. PubMed ID: 11488735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of urinary pyridinoline excretion with a specific enzyme-linked immunosorbent assay in normal adults and in metabolic bone diseases.
    Arbault P; Grimaux M; Pradet V; Preaudat C; Seguin P; Delmas PD
    Bone; 1995 Apr; 16(4):461-7. PubMed ID: 7605707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary pyridinoline and deoxypyridinoline in healthy children and in children with growth hormone deficiency.
    Fujimoto S; Kubo T; Tanaka H; Miura M; Seino Y
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1922-8. PubMed ID: 7775642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis.
    Delmas PD; Schlemmer A; Gineyts E; Riis B; Christiansen C
    J Bone Miner Res; 1991 Jun; 6(6):639-44. PubMed ID: 1887826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes of bone metabolic markers in patients with bone metastases: clinical significance in assessing bone response to chemotherapy.
    Wada S; Katayama Y; Yasutomo Y; Kugai N; Nagata N
    Intern Med; 1993 Aug; 32(8):611-8. PubMed ID: 8312657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease.
    Coleman RE; Houston S; James I; Rodger A; Rubens RD; Leonard RC; Ford J
    Br J Cancer; 1992 May; 65(5):766-8. PubMed ID: 1586605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic validity of bone metabolic markers for bone metastasis.
    Miura H; Yamamoto I; Takada M; Kigami Y; Ohta T; Yuu I; Hamanaka Y; Matsushita R; Morita R
    Endocr J; 1997 Oct; 44(5):751-7. PubMed ID: 9466334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.